This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.
April 19th, 2021
Pictura Bio announces £2.6 million in pre-seed funding from ScienceCreates Ventures
- Technology aims to improve speed, cost and accuracy of infectious disease diagnostics
- Funding will be used to expand team and further validate technology
“Our ability to take a sample from someone with an unknown infection and answer the open question ‘what do they have?’ within a minute is a gamechanger for infection diagnosis and treatment. We’ll start with respiratory viruses and expand from there. In parallel, we’ll be simplifying the workflow to move the test from the lab to point of care, which will represent a step change in the availability and cost of infectious disease diagnostics worldwide.”Ed Stacey, Managing Partner at IQ Capital Partners, added:
“The potential of OxDX’s technology to identify diseases ‘while you wait,' and roll out tests for new pathogens with just a software update is going to revolutionise diagnostics and patient treatment. This incredible team have already achieved an enormous amount and I’m looking forward to seeing the impact they have on the field of infectious disease diagnostics.”Dr Joanna Green, Principal at Ahren Innovation Capital, commented:
“We look forward to working with the OxDX team to achieve the full potential of their technology, operating at the intersection of machine learning and microscopy, applied to diagnostics. This type of transformative technology can have a huge positive impact on the world.”
- ‘Virus detection and identification in minutes using single-particle imaging and deep learning’, medRxiv
- ‘Rapid functionalisation and detection of viruses via a novel Ca 2+-mediated virus-DNA interaction’, Scientific Reports Nature Research